Experts are doubtful about claims of a breakthrough by a small listed biotech company.
When the small biotechnology company Biotron announced on July 1 that its recent research opened a new approach to treating hepatitis C, it had a ring of familiarity about it. In fact, its announcement to the Australian Stock Exchange repeated, almost word-for-word, research announcements made by academics overseas earlier this year.